SEC Comment Letter for RENOVARO INC. (RENB) (CIK 0001527728) (LNAI) — Oct 10, 2024

RENOVARO INC. (RENB) (CIK 0001527728)
Date: Oct. 10, 2024 · CIK: 0001527728 · Accession: 0000000000-24-011496

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-38758

Date

October 10, 2024

Author

Mark DyBul

Form

UPLOAD

Company

RENOVARO INC. (RENB) (CIK 0001527728)

Letter

October 10, 2024 Mark DyBul Chief Executive Officer Renovaro Biosciences Inc. 2080 Century Park East, Suite 906 Los Angeles, CA 90067 Re:Renovaro Biosciences Inc. Form 10-K for the Fiscal Year Ended June 30, 2023 Filed October 2, 2023 File No. 001-38758 Dear Mark DyBul: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

October 10, 2024
Mark DyBul
Chief Executive Officer
Renovaro Biosciences Inc.
2080 Century Park East, Suite 906
Los Angeles, CA 90067
Re:Renovaro Biosciences Inc.
Form 10-K for the Fiscal Year Ended June 30, 2023
Filed October 2, 2023
File No. 001-38758
Dear Mark DyBul:
            We have completed our review of your filings. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io